Is the AstraZeneca share price too high now? Here’s what you need to know

The demand for pharmaceutical companies’ stocks has surged dramatically. AstraZeneca (LSE:AZN) shares have been no exception. Investor enthusiasm was fuelled by hopes of a new Covid-19 vaccine. But isn’t the AstraZeneca share price already too high?  Why did the AstraZeneca share price rally? On Monday, the pharma giant resumed phase […]

The demand for pharmaceutical companies’ stocks has surged dramatically. AstraZeneca (LSE:AZN) shares have been no exception. Investor enthusiasm was fuelled by hopes of a new Covid-19 vaccine. But isn’t the AstraZeneca share price already too high? 

Why did the AstraZeneca share price rally?

On Monday, the pharma giant resumed phase 3 vaccine trials. As we all know, the company’s stock has been surging in recent months. That’s because people expect AstraZeneca to develop a Covid-19 vaccine. But is the future so bright for AstraZeneca and its vaccine?

Quite recently the FDA said AstraZeneca’s coronavirus vaccine trial in the US is still pending. That’s because the FDA is unsure if there is a big safety issue or not. So, many questions remain. Phase 3 vaccine trials don’t mean the vaccine will be available tomorrow. What’s more, the FDA’s investigation also suggests there are still many regulatory hurdles. That’s why the AstraZeneca share price surge isn’t quite reasonable, in my opinion.

But there’s one more issue. Everyone wants to develop an effective Covid-19 vaccine. For example, in Russia a coronavirus vaccine was developed and approved by the state. Phase 3 trials are still going on, however. Some companies are close to launching their vaccine too. For example, Johnson & Johnson is doing late-stage testing right now. But we’ve all read plenty of stories about the likes of Gilead Sciences and Moderna. The point I’m making is that no one has developed and launched an effective Covid-19 vaccine yet, and it’s hard to predict who’ll be the first one to do so.

Please don’t forget that developing a good treatment doesn’t mean it’ll be easy to commercialise. Some drugs, for example, are easy to copy. Many companies such as Teva Pharma produce generics in developing countries. They are much cheaper but the quality isn’t much worse.

The overvaluation problem

My colleague Kirsteen wrote a wonderful article about AstraZeneca shares. I fully agree that the company is one of the largest and greatest Footsie constituents.

 

At the same time, the multiples the company is trading at are incredibly high. In my view, investors are already certain AstraZeneca will develop a best-selling and profitable Covid-19 vaccine. Only in that case can the price-to-earnings (P/E) ratio of 104 be justified.

Let’s compare AstraZeneca to its peer GlaxoSmithKline (LSE:GSK). Both companies are large pharmaceutical businesses with large market shares. GlaxoSmithKline’s sales revenue in 2019 totaled £33.8bn, while AstraZeneca’s was just $24.4bn. AstraZeneca’s dividend yield is about 2.5%. In comparison, GlaxoSmithKline’s is over 5%. What’s more, GSK’s insiders bought some of their company’s shares in late July. AstraZeneca’s directors also acquired some of their firm’s stocks. But they did so in February and March when the stock market was crashing. And yet GlaxoSmithKline shares are trading at a P/E of just 16 as opposed to AstraZeneca’s 104.

I don’t think it’s fair. AstraZeneca shares are popular just because of the vaccine hopes, I think.      

Here’s what I’d do

I appreciate the fact AstraZeneca is a respectable FTSE 100 constituent. Indeed, it’s large and operating in a stable sector. But, in my view, it’s just too overvalued. So, I’d avoid its shares. I’d look through the Motley Fool’s excellent library for other investment ideas.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential…

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

More reading

Anna Sokolidou has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Gilead Sciences. The Motley Fool UK has recommended GlaxoSmithKline and Johnson & Johnson. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

The post Is the AstraZeneca share price too high now? Here’s what you need to know appeared first on The Motley Fool UK.

ASNF

Next Post

The Transparency Imperative: Reimagining Your Fundraising-to-Finance Strategy to Build Donor Trust

Thu Sep 17 , 2020
Nonprofit and education organizations alike have had their work cut out for them this year. With so many challenges hitting so quickly, it can feel like a non-stop effort just to stay in place. So first, let me say this: Thank you, to our nonprofit and our education customers. We […]